The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10317 malaria professionals are enjoying the free benefits of MalariaWorld today

Immunization

Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

February 11, 2020 - 16:26 -- Open Access
Author(s): 
Antje Blank, Kristin Fürle, Hermann Bujard, et al.
Reference: 
npj Vaccines 5, 10 (2020)

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant. Thirty-two healthy volunteers were vaccinated at least three times with MSP1 plus adjuvant, adjuvant alone, or placebo (24:4:4) to evaluate the safety and immunogenicity.

A Systematic Review of the Incremental Costs of Implementing a New Vaccine in the Expanded Program of Immunization in Sub-Saharan Africa

January 14, 2020 - 16:33 -- Open Access
Author(s): 
Brew J, Sauboin C
Reference: 
MDM Policy & Practice, 2019 Dec 19; 4(2):2381468319894546

The World Health Organization is planning a pilot introduction of a new malaria vaccine in three sub-Saharan African countries. To inform considerations about including a new vaccine in the vaccination program of those and other countries, estimates from the scientific literature of the incremental costs of doing so are important

Subscribe to RSS - Immunization